|Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017|
November 16, 2017
|FREMONT, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Michael Mulroy, President and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel in New York City. Asterias’ presentation is scheduled for Tuesday, November 28, 2017, at 12:30 p.m. Eastern Time.
A live webcast of the presentation will be ac... |
|Seasoned Financial Executive Joins OncoCyte as Chief Financial Officer|
November 15, 2017
|ALAMEDA, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Mitch Levine has been appointed Chief Financial Officer, effective November 15, 2017. With 33 years of experience in the financial industry and extensive expertise in fundraising for early stage companies Mr. Levine will be responsible for OncoCyte's finance and financial reporting activities.
“Mitch is an... |
|BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO|
November 15, 2017
|There were no treatment-related serious adverse events after 15 months
Signs of engraftment and cell survival have been maintained
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 15, 2017--
BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology
company focused on developing and commercializing products addressing
degenerative diseases, today announced that an abstract related to one
of its lead programs, OpRegen® for... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|